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:.:~~~. ...:.. sequence ofevents at the motor end-plate after the injection ofbotulinum toxin. In (a) the toxin has becomefixed to the motor nerve terminal and is represented by the cross-hatching. Axonal sprouting commences from the terminal (b) and the growing axon is wrapped in processes ofSchwann cells which separate itfrom the musclefibre. The bound toxin is gradually diluted out (c) and the axonforms new contacts with the musclefibre at some distancefrom the site ofthe original end-plate. The contacts are at first loose and without subneuralfolds ofsarcolemma but later become close and subneuralfolds are formed (d) botulinum toxin (Duchen 1970b) . Botulinum toxin was injected into the leg muscles and after the onset of paralysis the sciatic nerve was crushed and then allowed to regenerate. In these animals the axons distal to the lesion degenerated but regenerated from their intact proximal stumps and re-innervated the original end-plates. Within seven to ten days neuromuscular function was restored. The sequence of events was similar to that occurring after nerve crush in normal animals. The muscles did not become atrophied and the axons did not sprout beyond the end-plate excessively, in marked contrast to the picture found after the injection of toxin alone.
There are several points of interest in the consideration of the motor nerve sprouting induced by botulinum toxin. (1) The toxin causes paralysis without the destruction of motor axons or terminals. (2) Once motor nerve sprouting has begun it continues for several weeks before new end-plates are formed, unlike the re-innervation of structurally denervated muscle fibres on which a new motor nerve rapidly forms a functioning end-plate. (3) The nerve sprouting found after the injection of toxin seems to be proportional to the dose of toxin injected. (4) The nerve sprouting beyond the motor end-plates is abolished if, after the injection of toxin, the nerve is crushed and then allowed to regenerate. This implies that the degeneration and removal of the original blocked nerve terminals after the crush injury has allowed the removal of whatever it was that impaired neuromuscular transmission.
A hypothesis to account for the sequence of events might be summarized as in Fig 1. The toxin becomes fixed in an unknown way either to the pre-synaptic axolemma or to some component of the axoplasm of the motor nerve terminal, and there remains in its bound form blocking neuromuscular transmission. Only after sufficient new axonal tissue is formed by the growing motor nerve can transmission begin again at points along the axon where bound toxin has been 'diluted out'. The nerve growth induced by botulinum toxin can thus be regarded as a form of regeneration of the motor neurone, differing from previously studied forms of regeneration in the nervous system in that there has been no structural loss of tissue but only a loss of function within the nerve terminal. The mechanism which initiates motor nerve growth is still not known either in the present experimental situation or after axonal injury and it seems likely that some factor is common to both. Since motor nerve growth does not normally occur once neuromuscular connexions are formed it may be that contact with the muscle fibre permits an inhibitory mechanism to operate. Any interruption of this contact, whether structural or functional, may be responsible for the initiation of events leading to new nerve growth. During the last sixteen years there has been a marked change in attitudes of investigators towards the nature and extent of the information required before a compound intended for human or veterinary use is given for the first time to volunteers, patients or livestock. Twenty years ago it was commonplace for a research worker merely to investigate the desired pharmacological and chemotherapeutic properties in laboratory animals, then determine the LD50 value, the dose that kills 50% of the treated animals, probably in rodents, before either taking the new drug or trying it in patients.
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Today the volume of work needed to satisfy the standards both of research workers and of registering authorities is on a scale which seriously deters innovation of any drugs at all.
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My first example of drug toxicity was not detected during the primary studies in the laboratory, but resulted from the administration of compounds belonging to a series of bis (p-aminophenoxy) alkanes (Fig 1) . These compounds had been shown to be active against experimental schistosomiasis, and were reported in a series of papers by Caldwell & Standen (1956) Raison & Standen (1954, 1955) , and Standen & Walls (1956) . No untoward effect had been noted in mice given therapeutic doses, nor was there any immediate complaint from the research workers who ingested some of the compounds before they went off to Africa to study them clinically. Certain minor symptoms occurred, however, and this suggested that further investigations of this chemical series were necessary before proceeding further. Compounds of this class were given orally to cats and after several days the cats were thought to be blind; the pupillary reflexes were absent, and the animals avoided obstacles when in familiar surroundings, but bumped into things when the surroundings were unfamiliar. On ophthalmoscopic examination the fundus showed changes resembling retinitis pigmentosa. Rabbits were also dosed and pigmented epithelium were damaged (Goodwin et al. 1957 , Edge et al. 1956 , Ashton 1957 . Sorsby & Nakajima (1958) observed similar effects in their experiments on retinal injury. Nimmo-Smith (1970) drew attention to the role of alcohol dehydrogenase in the causation of blindness by these compounds. Since this occurrence we have always examined the fundi of animals of at least one mammalian species before investigating the drug in the definitive animal.
In the late 1950s I took part in investigations of a series of 8-aminoquinolines and examined serial blocks from brains fixed by perfusion. I also examined the retina.
Eight-aminoquinolines have been used for the treatment of malaria and one of the most successful was pamaquine (Fig 3) , first given to man in 1926 and reported to this Society in 1932 by Schulemann. Neurotoxicity had been reported by Loken & Haymaker in 1949. Compounds belonging to this series were given orally to rhesus or cynomolgus monkeys. Some of these animals became blind. Extensive brain damage occurred with some members of the series, thus confirming Schmidt's findings (Schmidt & Schmidt 1948 , 1951 . The blindness was associated with damage to the lateral geniculate body and no damage to the retina was found.
The third example poses different problems and concerns hexachlorophane (Fig 4) in sheep and cattle. This compound has been used in veterinary practice since about 1961 and is useful for control of flukes. Mr J C Malone and I have already drawn attention to its ability to cause blindness (Udall & Malone 1970) . Groups of sheep were dosed by the oral, abomasal or ruminal route with single doses of hexachlorophane; the doses ranged from 20 to 80 mg/kg. In addition a small number of calves approximately six months old were dosed by the oral route. Acute toxic symptoms in both species appeared within twelve to thirty hours of treatment. In a proportion of the surviving animals, loss of visual acuity and of pupillary reflexes was observed. Ophthalmoscopic examination of the fundus of treated sheep revealed, in a proportion, transient cedema of the optic disc. The changes were observed approximately twentyfour hours after dosing and disappeared fortyeight to seventy-two hours later. The loss of pupillary response to light was usually noted about seventy-two hours after treatment, the pupils of affected animals being grossly dilated. No recovery of pupillary response was observed in affected animals up to four months after dosing. Other animals have more recently been examined, using a retino-electroencephalograph, and no action potentials were registered. It is tempting to suggest that these animals pass through a phase of acute raised intracranial pressure, and this suggestion is supported by the post-mortem finding of dilated lateral ventricles, and of transient papilleedema seen soon after dosing. Malone has, however, been unable to confirm the raised pressure by direct measurement. Ungulates such as sheep and cattle may have anatomical features at the optic foramen which favour the development of optic nerve compression ( Fig 5) . When high ,.. doses of hexachlorophane were given to young rats, exophthalmos occurred, whilst, in older rats, cerebral cedema was found. These observations show that the visual pathways are vulnerable to drug toxicity at least from the retina to the lateral geniculate body. This last experience introduced two main problems that face a toxicologist, the significance of species differences in response to drugs and the dangers of extrapolating from biological observations on chemical analogues. In the case of hexachlorophane, the differences in response are probably due to variations in anatomical structure: in general, differences of effect are mostly due to metabolic variation. For instance, in the rat, doses of 10 mg/kg per day digoxin may be given for periods up to three months without serious consequences but, in the dog, onehundredth of this dose can be lethal. Morphine in man and dog is a useful narcotic, whereas it is excitatory in the cat. Sulphonamides produce chemical thyroidectomy in rats, but are less effective in this respect in dogs and monkeys, and I am assured that no such effect has been reported in man. The presence of atropine esterases enables the rabbit to ingest belladonna with impunity. Many more examples of this kind could be cited, but it is also clear that small chemical differences can be equally important. Few of us have much hesitation in drinking ethyl alcohol, but what about methyl alcohol? Primary, secondary and tertiary amines of the di-phenoxy-alkanes have a decreasing order of retinotoxicity. Benzene and toluene differ in their potentiality for producing bone marrow dyscrasia. We do not need to be reminded of the conspicuous differences between the biological effects of heroin and codeine, or of morphine and nalorphine which are due to simple chemical differences. I would end my contribution by referring to current practice evolved within the Wellcome Foundation before a new compound is released for investigation. The ABPI document (Association of the British Pharmaceutical Industry 1964) and the recent article by Hanley et al. (1970) give our views on this subject. I hope I have demonstrated to you the considerable change in attitude and practice in the information obtained before a new drug is now thought fit for human or veterinary trial.
